CoChat

VEGF-R2/Caveolin-1 Pathway of Undifferentiated ARPE-19 Retina Cells: A Potential Target as Anti-VEGF-A Therapy in Wet AMD by Resvega, an Omega-3/Polyphenol Combination

Open access
Courtaut, Flavie, Scagliarini, Alessandra, Aires, Virginie, Cornebise, Clarisse, Pais de Barros, Jean-Paul, Olmiere, Céline, Delmas, Dominique · 2021 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Age-related macular degeneration (AMD) is one of the main causes of deterioration in vision in adults aged 55 and older. In spite of therapies, the progression of the disease is often observed without reverse vision quality. In the present study, we explored whether, in undifferentiated ARPE-19 retinal cells, a disruption of the VEGF receptors (VEGF-R)/caveolin-1 (Cav-1)/protein kinases pathway could be a target for counteracting VEGF secretion. We highlight that Resvega®, a combination of omega-3 fatty acids with an antioxidant, resveratrol, inhibits VEGF-A secretion in vitro by disrupting the dissociation of the VEGF-R2/Cav-1 complex into rafts and subsequently preventing MAPK activation. Moreover, DNA ChIP analysis reveals that this combination prevents the interaction between AP-1 and vegf-a and vegf-r2 gene promoters. By these pathways, Resvega could present a potential interest as nutritional complementation against AMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms22126590

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 RSV/ω3 fatty acids combination disrupts VEGF-A secretion and inhibits phosphorylation of its receptor. (A) Determination of RSG and RSV effects on human retinal ARPE-19 cells. After treatment of ARPE-19 cells with increasing of RSG (0; 0.6; 3; 6; and 12 µM) or RSV (20 µM) concentrations at 37 °C for 24 h, the percentage of cell viability was determined by crystal violet assay. Results are expressed as a percentage of control (mean ± standard deviation of three independent experiments with n = 10). (B) ARPE-19 retina cells were treated for 24 h without serum with RSG (12 µM) or RSV (20 µM). VEGF-A secretion was measured in cell medium by ELISA. The data are mean ± S.D. of four independent experiments with n = 10. p values were determined by one-way ANOVA followed by Tukey’s multiple comparison test. * = p < 0.05; ** = p < 0.01; *** = p < 0.001. (C) ARPE-19 retina cells were treated without (Co) or with H2O2 (200 µM) for 24 h in combination or not with RSG (12 µM) or RSV (20 µM). As in (A) VEGF-A secretion was measured in cell medium by ELISA. The data are mean ± S.D. of four independent experiments with n = 10. p values were determined by one-way ANOVA followed by Tukey’s multiple comparison test. * = p < 0.05; ** = p < 0.01; *** = p < 0.001. (D) Immunoblot analysis of VEGF-R1, VEGF-R2, phospho Y1054 VEGF-R2, phospho Y951 VEGF-R2, phospho Y115 VEGF-R2 in ARPE-19 cell line after treatment without (Co) or with RSG (0.6, 3, 6, 12 µM) or with RSV (20 µM) for 24 h. β-actin was used as the loading control. (E) Densitometry quantification of western blots. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001 and n.s.: not significant.
Figure 1 RSV/ω3 fatty acids combination disrupts VEGF-A secretion and inhibits phosphorylation of its receptor. (A) Determination of RSG and RSV effects on human retinal ARPE-19 cells. After treatment of ARPE-19 cells with increasing of RSG (0; 0.6; 3; 6; and 12 µM) or RSV (20 µM) concentrations at 37 °C for 24 h, the percentage of cell viability was determined by crystal violet assay. Results are expressed as a percentage of control (mean ± standard deviation of three independent experiments with n = 10). (B) ARPE-19 retina cells were treated for 24 h without serum with RSG (12 µM) or RSV (20 µM). VEGF-A secretion was measured in cell medium by ELISA. The data are mean ± S.D. of four independent experiments with n = 10. p values were determined by one-way ANOVA followed by Tukey’s multiple comparison test. * = p < 0.05; ** = p < 0.01; *** = p < 0.001. (C) ARPE-19 retina cells were treated without (Co) or with H2O2 (200 µM) for 24 h in combination or not with RSG (12 µM) or RSV (20 µM). As in (A) VEGF-A secretion was measured in cell medium by ELISA. The data are mean ± S.D. of four independent experiments with n = 10. p values were determined by one-way ANOVA followed by Tukey’s multiple comparison test. * = p < 0.05; ** = p < 0.01; *** = p < 0.001. (D) Immunoblot analysis of VEGF-R1, VEGF-R2, phospho Y1054 VEGF-R2, phospho Y951 VEGF-R2, phospho Y115 VEGF-R2 in ARPE-19 cell line after treatment without (Co) or with RSG (0.6, 3, 6, 12 µM) or with RSV (20 µM) for 24 h. β-actin was used as the loading control. (E) Densitometry quantification of western blots. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001 and n.s.: not significant.CC BY · PubMed Central
Figure 2 Disruption of VEGF-R2/Cav-1 dissociation into lipid rafts by RSV/ω3 fatty acids combination. (A) ARPE-19 retina cells were treated for 24 h by increasing concentrations of RSG (0.6, 3, 6, 12 µM) or with RSV (20 µM) for 24 h. A representative blot of Cav-1 and phospho-Cav-1 (p-Cav-1) is shown from three independent experiments. β-actin was used as a loading control. Densitometry quantification of western blotting is expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. ** p < 0.01, *** p < 0.001 and n.s.: not significant. (B) ARPE-19 cells were left untreated (Co) or treated with 0.6 µM RSG for 24 h before fluorescence microscopy analysis of caveolin-1 (Cav-1) and VEGF-R2 coexpression. A representative image of three independent experiments is shown. (C) Lipid composition of ARPE-19 cell lysate fractions after RSG (12 µM) or RSV (20 µM) treatment for 24 h. Cholesterol (black bars) and sphingomyelin (white bars) were expressed in µg/mL of a fraction. Data are expressed as the mean fold induction ± SEM of three independent experiments. (D) The representative blot of the expression of indicated proteins in the above-defined fractions is shown from three independent experiments. (E) Densitometry quantification of western blotting. Data are expressed as the mean fold induction ± SEM of three independent experiments.
Figure 2 Disruption of VEGF-R2/Cav-1 dissociation into lipid rafts by RSV/ω3 fatty acids combination. (A) ARPE-19 retina cells were treated for 24 h by increasing concentrations of RSG (0.6, 3, 6, 12 µM) or with RSV (20 µM) for 24 h. A representative blot of Cav-1 and phospho-Cav-1 (p-Cav-1) is shown from three independent experiments. β-actin was used as a loading control. Densitometry quantification of western blotting is expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. ** p < 0.01, *** p < 0.001 and n.s.: not significant. (B) ARPE-19 cells were left untreated (Co) or treated with 0.6 µM RSG for 24 h before fluorescence microscopy analysis of caveolin-1 (Cav-1) and VEGF-R2 coexpression. A representative image of three independent experiments is shown. (C) Lipid composition of ARPE-19 cell lysate fractions after RSG (12 µM) or RSV (20 µM) treatment for 24 h. Cholesterol (black bars) and sphingomyelin (white bars) were expressed in µg/mL of a fraction. Data are expressed as the mean fold induction ± SEM of three independent experiments. (D) The representative blot of the expression of indicated proteins in the above-defined fractions is shown from three independent experiments. (E) Densitometry quantification of western blotting. Data are expressed as the mean fold induction ± SEM of three independent experiments.CC BY · PubMed Central
Figure 3 RSG affects the Raf-MAP kinases pathway in retinal cells. (A) Immunoblot analysis of c-Raf, phospho c-Raf (p-Raf), MEK, phospho MEK (p-MEK), ERK 1/2, phospho-ERK 1/2 (p ERK 1/2) in RSG-treated ARPE-19 cells with increasing concentration (0.6, 3, 6, 12 µM) or with RSV (20 µM) for 24 h. β-actin was used as a loading control. (B) Densitometry quantification of western blotting. Data are expressed as the mean fold induction ± SEM of three independent experiments. P values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05, ** p < 0.01 and *** p < 0.001, n.s.: not significant.
Figure 3 RSG affects the Raf-MAP kinases pathway in retinal cells. (A) Immunoblot analysis of c-Raf, phospho c-Raf (p-Raf), MEK, phospho MEK (p-MEK), ERK 1/2, phospho-ERK 1/2 (p ERK 1/2) in RSG-treated ARPE-19 cells with increasing concentration (0.6, 3, 6, 12 µM) or with RSV (20 µM) for 24 h. β-actin was used as a loading control. (B) Densitometry quantification of western blotting. Data are expressed as the mean fold induction ± SEM of three independent experiments. P values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05, ** p < 0.01 and *** p < 0.001, n.s.: not significant.CC BY · PubMed Central
Figure 4 RSG down-regulates nuclear transcriptional factors c-Jun and c-Fos and their phosphorylated forms. (A) RT-qPCR mRNA expression analysis of c-jun and c-fos. Data represent three independent experiments. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001 and n.s.: not significant. (B) Immunoblot analysis of c-Jun, phospho Ser63 c-Jun (pSer63 c-Jun), phospho Ser73 c-Jun (pSer73 c-Jun), c-Fos, phospho-c-Fos (p-c-Fos) in RSG-treated ARPE-19 cells with increasing concentration (0.6, 3, 6, 12 µM) or with RSV (20 µM) for 24 h. β-actin was used as the loading control. (C) Densitometry quantification of western blotting. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05, ** p < 0.01 and *** p < 0.001.
Figure 4 RSG down-regulates nuclear transcriptional factors c-Jun and c-Fos and their phosphorylated forms. (A) RT-qPCR mRNA expression analysis of c-jun and c-fos. Data represent three independent experiments. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001 and n.s.: not significant. (B) Immunoblot analysis of c-Jun, phospho Ser63 c-Jun (pSer63 c-Jun), phospho Ser73 c-Jun (pSer73 c-Jun), c-Fos, phospho-c-Fos (p-c-Fos) in RSG-treated ARPE-19 cells with increasing concentration (0.6, 3, 6, 12 µM) or with RSV (20 µM) for 24 h. β-actin was used as the loading control. (C) Densitometry quantification of western blotting. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05, ** p < 0.01 and *** p < 0.001.CC BY · PubMed Central
Figure 5 RSG inhibits the translocation of phosphorylated c-Jun forms into the nucleus of ARPE-19 cells. (A) Immunofluorescence analysis of expression and localization of c-Fos, c-Jun, and phospho Ser63 c-Jun, phospho Ser 73 c-Jun into untreated (Co) or treated ARPE-19 retina cells with RSG (12 µM) or with RSV (20 µM) for 24 h. Left panel, representative images of specific proteins expression (green fluorescence) counterstaining with Hoechst 33342 (nuclei, blue). Right panel quantification of a specific protein on merged pictures (300 cells per line) with Image J software. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. ** p < 0.01, *** p < 0.001 and n.s.: not significant. (B) Representative blot of c-Jun, phospho Ser63 c-Jun (pSer63 c-Jun), phospho Ser73 c-Jun (pSer73 c-Jun) protein expression in RSG (12 µM)-treated ARPE-19 cells or with RSV (20 µM) for 24 h. Nuclear fractions (N) and cytosolic (C) fractions are shown from three independent experiments. Densitometry quantification of western blotting. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. ** p < 0.01 and *** p < 0.001.
Figure 5 RSG inhibits the translocation of phosphorylated c-Jun forms into the nucleus of ARPE-19 cells. (A) Immunofluorescence analysis of expression and localization of c-Fos, c-Jun, and phospho Ser63 c-Jun, phospho Ser 73 c-Jun into untreated (Co) or treated ARPE-19 retina cells with RSG (12 µM) or with RSV (20 µM) for 24 h. Left panel, representative images of specific proteins expression (green fluorescence) counterstaining with Hoechst 33342 (nuclei, blue). Right panel quantification of a specific protein on merged pictures (300 cells per line) with Image J software. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. ** p < 0.01, *** p < 0.001 and n.s.: not significant. (B) Representative blot of c-Jun, phospho Ser63 c-Jun (pSer63 c-Jun), phospho Ser73 c-Jun (pSer73 c-Jun) protein expression in RSG (12 µM)-treated ARPE-19 cells or with RSV (20 µM) for 24 h. Nuclear fractions (N) and cytosolic (C) fractions are shown from three independent experiments. Densitometry quantification of western blotting. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. ** p < 0.01 and *** p < 0.001.CC BY · PubMed Central
Figure 6 RSG inhibits vegf-a and vegf-r2 mRNA expressions through a disruption of the AP-1 binding sites. ARPE-19 cells were untreated (Co) or treated with RSG (12 µM) or with RSV (20 µM) for 24 h. (A) Upper panel, analysis on the putative binding sites of AP-1 on the vegf-a gene promoter. Down panel, ChIP analysis of the interaction between AP-1 and the vegf promoter in ARPE-19 cells. Analysis of the putative B.S.3 for AP-1 on the vegf promoter (−4976 −4964) is shown. For the putative B.S.1, B.S.2, B.S.4, and B.S.5, any amplification was obtained. (B) RT-qPCR mRNA expression analysis of vegf-a. Data represent three independent experiments. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05, ** p < 0.01 and *** p < 0.001. (C) Upper panel, analysis of the putative binding sites of AP-1 on the vegf-r2 gene promoter. Down panel, ChIP analysis of the interaction between AP-1 and the vegf-r2 promoter in ARPE-19 cells. Analysis of the putative B.S.5 and B.S.6 for AP-1 on the vegf-r2 promoter (−3942, −3930, and −3864, −3852, respectively) is shown. For the putative B.S.1, B.S.2, B.S.3, and B.S.4, any amplification was obtained. (D) RT-qPCR mRNA expression analysis of vegf-r2. Data represent three independent experiments. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05, ** p < 0.01 and *** p < 0.001.
Figure 6 RSG inhibits vegf-a and vegf-r2 mRNA expressions through a disruption of the AP-1 binding sites. ARPE-19 cells were untreated (Co) or treated with RSG (12 µM) or with RSV (20 µM) for 24 h. (A) Upper panel, analysis on the putative binding sites of AP-1 on the vegf-a gene promoter. Down panel, ChIP analysis of the interaction between AP-1 and the vegf promoter in ARPE-19 cells. Analysis of the putative B.S.3 for AP-1 on the vegf promoter (−4976 −4964) is shown. For the putative B.S.1, B.S.2, B.S.4, and B.S.5, any amplification was obtained. (B) RT-qPCR mRNA expression analysis of vegf-a. Data represent three independent experiments. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05, ** p < 0.01 and *** p < 0.001. (C) Upper panel, analysis of the putative binding sites of AP-1 on the vegf-r2 gene promoter. Down panel, ChIP analysis of the interaction between AP-1 and the vegf-r2 promoter in ARPE-19 cells. Analysis of the putative B.S.5 and B.S.6 for AP-1 on the vegf-r2 promoter (−3942, −3930, and −3864, −3852, respectively) is shown. For the putative B.S.1, B.S.2, B.S.3, and B.S.4, any amplification was obtained. (D) RT-qPCR mRNA expression analysis of vegf-r2. Data represent three independent experiments. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test. * p < 0.05, ** p < 0.01 and *** p < 0.001.CC BY · PubMed Central
Figure 7 Suggested model to counteract VEGF-A secretion in retinal cells with AMD phenotype by nutraceuticals. Contrary to the physiopathological mechanism observed in retinal cells mimicking AMD, nutraceutical with resveratrol/ω3 fatty acids combination promotes (1) VEGF-R2 relocalization into lipid rafts and its binding with Cav-1, a constitutive protein of lipid rafts. This VEGF-R2-Cav-1 association, which acts as a negative regulator of the VEGF-A signaling cascade, prevents (2) the activation of MAP kinase pathway and subsequently decreases (3) phosphorylation of transcriptional nuclear factors such as c-Jun. Reduction of phospho-c-Jun level is associated with a (4) disruption of c-Jun into the nucleus. Furthermore, nutraceuticals also seemed to disrupt and antagonize AP-1 binding sites on the promoters of vegf and vegfr genes and contribute to the decrease in their mRNA and protein levels.
Figure 7 Suggested model to counteract VEGF-A secretion in retinal cells with AMD phenotype by nutraceuticals. Contrary to the physiopathological mechanism observed in retinal cells mimicking AMD, nutraceutical with resveratrol/ω3 fatty acids combination promotes (1) VEGF-R2 relocalization into lipid rafts and its binding with Cav-1, a constitutive protein of lipid rafts. This VEGF-R2-Cav-1 association, which acts as a negative regulator of the VEGF-A signaling cascade, prevents (2) the activation of MAP kinase pathway and subsequently decreases (3) phosphorylation of transcriptional nuclear factors such as c-Jun. Reduction of phospho-c-Jun level is associated with a (4) disruption of c-Jun into the nucleus. Furthermore, nutraceuticals also seemed to disrupt and antagonize AP-1 binding sites on the promoters of vegf and vegfr genes and contribute to the decrease in their mRNA and protein levels.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 17

Metadata

Authors
Courtaut, F., Scagliarini, A., Aires, V., Cornebise, C., Pais de Barros, J.-P., Olmiere, C., & Delmas, D.
Affiliations
  • Inserm (FR)
  • Université de Bourgogne Franche-Comté, 21000 Dijon, France
  • Laboratoires Thea, 12 Rue Louis-Blériot, 63000 Clermont-Ferrand, France
Corresponding author
Delmas, Dominique
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-06-19
Volume
22
Issue
12
Pages
6590
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3174973673
Cited by
17
References
51
Citations by year
2026: 2 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 1
FWCI
2.69
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Agence Nationale de la Recherche (ANR-11-LABX-0021)
  • Association Nationale de la Recherche et de la Technologie
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Caveolin-1 and cellular processes
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
Keywords
age-related macular degeneration, VEGF-A, VEGFR2, caveolin-1, omega-3 fatty acids, resveratrol, MAPK signaling, lipid rafts, AP-1 transcription factor, anti-VEGF therapy, dietary intervention
MeSH terms
Cell Line, Drug Evaluation, Preclinical, Humans, Macular Degeneration, Retina, Transcription Factor AP-1, MAP Kinase Signaling System, Vascular Endothelial Growth Factor Receptor-2, Caveolin 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: VEGF-R2/Caveolin-1 Pathway of Undifferentiated ARPE-19 Retina Cells: A Potential Target as Anti-VEGF-A Therapy in Wet AMD by Resvega, an Omega-3/Polyphenol Combination. https://app.cochat.ai/papers/10.3390/ijms22126590
The paper
Courtaut, F., Scagliarini, A., Aires, V., Cornebise, C., Pais de Barros, J.-P., Olmiere, C., & Delmas, D. (2021). VEGF-R2/Caveolin-1 Pathway of Undifferentiated ARPE-19 Retina Cells: A Potential Target as Anti-VEGF-A Therapy in Wet AMD by Resvega, an Omega-3/Polyphenol Combination. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22126590

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.